But the needed information can still be obtained, minimally invasive even, by the analysis of circulating tumor cells (CTC). As cancer spreads via the bloodstream, these tumor cells found in the blood of metastatic cancer patients represent the most active part of the disease. However, due to the low number of tumor cells present in circulation, in many blood samples from metastatic patients no tumor cells are detected, preventing treatment target analysis.

To increase the detection sensitivity and reliably obtainment therapy target expression information, FETCH detects and analysis circulating tumor cells from the patients entire blood volume. For this, they use leukapheresis as a method of sample collection. With leukapheresis, cancer cells can be from the full blood volume, leading to increased CTC detection. The use of this readily available and approved technology facilitates simpler implementation. Early clinical testing in prostate cancer already demonstrated the technologies potential, realizing a 42-fold increase in the number of detected tumor cells compared to the standard blood tube processing.

FETCH was the winner of the 2024 spring edition of the Venture Challenge and has up to now developed its technology and business case using non-dilutive funding. To speed up development and initiate pharmaceutical research sales, FETCH now offers early stage investors the opportunity to partake in its upcoming seed round.